Mytesi
Ended Awarded Last action
- Contract number
- 36C26025F0036
- Awardee
-
Napo Pharmaceuticals Inc. UEI GNMTLLK5JQE5
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $42,225
Award facts
- Contract value 100% obligated
- $42,225.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- San Francisco, CA 94104, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $42,225 |
About this award
This federal contract award is for the delivery of Mytesi, a 125mg oral tablet used to treat non-infectious diarrhea in adult HIV/AIDS patients receiving antiretroviral therapy. The contract was awarded to Napo Pharmaceuticals Inc., a pharmaceutical company and subsidiary of Jaguar Health Inc. that specializes in developing and supplying pharmaceutical products for gastrointestinal disorders.
The contract, valued at $42,225.25, is a firm fixed-price delivery order with an ultimate completion date of September 30, 2025. It was awarded on October 1, 2024 by the Department of Veterans Affairs (VA), specifically the Veterans Integrated Service Network 20, a civilian agency. This contract is not associated with a set-aside designation, indicating Napo Pharmaceuticals competed in an open market procurement. The contract is part of Napo Pharmaceuticals' Federal Supply Schedule (FSS) contract under Schedule 65 IB for drugs, pharmaceuticals, and hematology-related products, which runs from August 1, 2023 through July 31, 2028 and has a total value of $1,151,660. This multiple-award indefinite delivery vehicle (IDV) contract allows VA healthcare facilities nationwide to efficiently order the specialized Mytesi medication to support the VA's commitment to providing critical pharmaceutical products for veteran patients.
Quick answers
Who was awarded contract 36C26025F0036?
36C26025F0036 was awarded to Napo Pharmaceuticals Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on October 1, 2024.
How much is contract 36C26025F0036 worth?
The government has obligated $42,225 on 36C26025F0036.
Is contract 36C26025F0036 an order under another contract?
Yes. 36C26025F0036 is a delivery order under 36F79723D0158, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0036 competed?
The extent of competition for 36C26025F0036 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award